108 Chapter 5 References 1. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19 Preliminary Report. New England Journal of Medicine NEJMoa2021436 (2020) doi:10.1056/ NEJMoa2021436. 2. The REMAP-CAP Investigators. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. New England Journal of Medicine 384, 1491–1502 (2021). 3. The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group et al. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA 326, 499 (2021). 4. Stukas, S. et al. Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study. The Lancet Regional Health - Americas 100228 (2022) doi:10.1016/j.lana.2022.100228. 5. The RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet (London, England) 397, 1637–1645 (2021). 6. Stichting Werkgroep Antibioticabeleid. Medicamenteuze behandeling voor patiënten met COVID-19 (infectie met SARSCoV-2). https://swab.nl/nl/covid-19#to_43 (2021). 7. Ledingham, J. M., MacPhie, E. & Bosworth, A. Covid-19: surging demand for some arthritis drugs. BMJ n2700 (2021) doi:10.1136/bmj.n2700. 8. Moes, D. J. A. R. et al. Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study. Clinical Pharmacokinetics 61, 231–247 (2022). 9. Strohbehn, G. W. et al. COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia. Clinical Pharmacology and Therapeutics 109, 688–696 (2021). 10. Landelijk Coördinatiecentrum Geneesmiddelen. Tussentijdse levering sarilumab; aangepast behandeladvies IL6-remmers. https://nvza.nl/wp-content/uploads/LCG-alert-211122_DEF.pdf (2021). 11. Landelijk Coördinatiecentrum Geneesmiddelen. Borgen continuïteit behandeling met IL-6remmers. https://nvza.nl/wp-content/uploads/IL-6-alert-LCG-alert-211112-def.pdf (2021). 12. Vocht, F. de et al. Conceptualising natural and quasi experiments in public health. BMC Medical Research Methodology 21, 32 (2021). 13. Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases 40, 373–383 (1987). 14. RIVM. Covid-19 rapportage van SARS-CoV-2 varianten in nederland via de aselecte steekproef van RT-PCR positieve monsters in de nationale kiemsurveillance. (2021). 15. Craig, P., Katikireddi, S. V., Leyland, A. & Popham, F. Natural Experiments: An Overview of Methods, Approaches, and Contributions to Public Health Intervention Research. Annual Review of Public Health 38, 39–56 (2017). 16. Altman, D. G. & Andersen, P. K. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 319, 1492–1495 (1999). 17. Peng, J. et al. Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: A systematic review and meta-analysis. Reviews in Medical Virology 32, (2022). 18. Kumar, P. N. et al. Safety and Efficacy of Tocilizumab 4 or 8 mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial. Open Forum Infectious Diseases 9, ofab608 (2022). 19. Florensa, D. et al. Severity of COVID-19 cases in the months of predominance of the Alpha and Delta variants. Scientific Reports 12, 15456 (2022).
RkJQdWJsaXNoZXIy MTk4NDMw